Patient Treatment Verification Research Articles

MRI-only brain radiotherapy verification using cone beam computed tomography

Introduction CBCT are frequently used for patient treatment verification. Hence, generated synthetic-CT (sCT) for MRI-only treatment planning workflow needs to be assessed for image guided radiation therapy (IGRT) using CBCT as well. Purpose For brain cancer patients, we investigated the effectiveness of using sCT that are generated from MRI instead of CT for CBCT-based IGRT. Material/methods Twelve patients with co-registered CT and conventional MRI were used to compute a library of patches. For three patients with two CBCT each, two sCT were generated from MRI using “non-local means” patch-based method (NMPBM) or “sparse” patch-based method (SPBM). CT and sCT alignments with CBCT were performed with MI-Powell. MI-Powell performs Powell optimization of mutual information between volumes and estimates alignment Euler angles and translation. Rigid transformations obtained for CT/CBCT registration were considered as the gold standard. Mean Target Registration Error (mTRE) obtained for sCT/CBCT alignment was computed. mTRE is the average distance between transformed CBCT voxels centers, within head region, by estimated and gold transformation respectively. Moreover, the average errors of displacement (Δ t ) and orientation (Δ θ ) from CT/CBCT registration transformation were computed. Results For sCT NMPBM /CBCT registration assessment, average mTRE = 1.36 ± 0.29 mm, Δ t = 0.92 ±0.2 mm and Δ θ = 1.02 ±0.34°. For sCT SPBM /CBCT registration assessment, average mTRE = 1.4 ± 0.3 mm, Δ t = 0.91 ± 0.21 mm and Δ θ = 1.08 ± 0.43°. Both NMPBM and SPBM were therefore accurate and gave an intermediate sCT suitable for CBCT-based IGRT. Conclusion Based on our results for brain site, CBCT can be used for patient position verification with sCT as a reference. Further work will be done for assessment in other clinical sites with challenging organ motion.

SU-G-BRB-06: Commissioning and Evaluation of EPID-Based in Vivo Dosimetry Software Using a Tissue-Maximum Ratio Approach

Purpose: To commission and evaluate an in vivo EPID-based transit dosimetry software (EPIgray, DOSIsoft, Cachan, France) using simple fields and TG119-based IMRT treatment plans. Methods: EPIgray was commissioned on a Truebeam based on finite tissue-maximum ratio (fTMR) measurements with solid water blocks of thicknesses between 0 and 37 cm. Field sizes varied from 2×2 to 20×20 cm2. Subsequently, treatment plans of single and opposed beams with field sizes between 4×4 and 15×15 cm2 as well as IMRT plans were measured to evaluate the dose reconstruction accuracy. Single field dose predictions were made for anterior-posterior and lateral beams. IMRT plans were created based on TG119 recommendations. The reconstructed dose was compared to the planned dose for selected points at isocenter and away from isocenter. Results: For single square fields, the dose in EPIgray was reconstructed within 3% accuracy at isocenter relative to the planned dose. Similarly, the relative deviation of the total dose was accurately reconstructed within 3% for all IMRT plans with points placed inside a high dose region near the isocenter. Predictions became less accurate than 5% when the evaluation point was outside the majority of IMRT beam segments. Additionally, points 5 cm or more away from the isocenter or within an avoidance structure were predicted less reliably. Conclusion: EPIgray formalism accuracy is adequate for an efficient error detection system. It provides immediate intra-fractional feedback on the delivery of treatment plans without affecting the treatment beam. Besides the EPID, no additional hardware is required, which makes it accessible to all clinics. The software evaluates point dose measurements to verify treatment plan delivery and patient positioning within 5% accuracy, depending on the placement of evaluation points. EPIgray is not intended to replace patient-specific quality assurance but should be utilized as an additional layer of safety for continuous patient treatment verification. This research is supported by DOSIsoft.

Clinical Experience and Evaluation of Patient Treatment Verification With a Transit Dosimeter

To prospectively evaluate a protocol for transit dosimetry on a patient population undergoing intensity modulated radiation therapy (IMRT) and to assess the issues in clinical implementation of electronic portal imaging devices (EPIDs) for treatment verification. Fifty-eight patients were enrolled in the study. Amorphous silicon EPIDs were calibrated for dose and used to acquire images of delivered fields. Measured EPID dose maps were back-projected using the planning computed tomographic (CT) images to calculate dose at prespecified points within the patient and compared with treatment planning system dose offline using point dose difference and point γ analysis. The deviation of the results was used to inform future action levels. Two hundred twenty-five transit images were analyzed, composed of breast, prostate, and head and neck IMRT fields. Patient measurements demonstrated the potential of the dose verification protocol to model dose well under complex conditions: 83.8% of all delivered beams achieved the initial set tolerance level of ΔD of 0±5cGy or %ΔD of 0%±5%. Importantly, the protocol was also sensitive to anatomic changes and spotted that 3 patients from 20 measured prostate patients had undergone anatomic change in comparison with the planning CT. Patient data suggested an EPID-reconstructed versus treatment planning system dose difference action level of 0%±7% for breast fields. Asymmetric action levels were more appropriate for inversed IMRT fields, using absolute dose difference (-2±5cGy) or summed field percentage dose difference (-6%±7%). The invivo dose verification method was easy to use and simple to implement, and it could detect patient anatomic changes that impacted dose delivery. The system required no extra dose to the patient or treatment time delay and so could be used throughout the course of treatment to identify and limit systematic and random errors in dose delivery for patient groups.

Has the use of computers in radiation therapy improved the accuracy in radiation dose delivery?

Purpose: It is well recognized that computer technology has had a major impact on the practice of radiation oncology. This paper addresses the question as to how these computer advances have specifically impacted the accuracy of radiation dose delivery to the patient. Methods: A review was undertaken of all the key steps in the radiation treatment process ranging from machine calibration to patient treatment verification and irradiation. Using a semi-quantitative scale, each stage in the process was analysed from the point of view of gains in treatment accuracy. Results: Our critical review indicated that computerization related to digital medical imaging (ranging from target volume localization, to treatment planning, to image-guided treatment) has had the most significant impact on the accuracy of radiation treatment. Conversely, the premature adoption of intensity-modulated radiation therapy has actually degraded the accuracy of dose delivery compared to 3-D conformal radiation therapy. While computational power has improved dose calibration accuracy through Monte Carlo simulations of dosimeter response parameters, the overall impact in terms of percent improvement is relatively small compared to the improvements accrued from 3-D/4-D imaging. Conclusions: As a result of computer applications, we are better able to see and track the internal anatomy of the patient before, during and after treatment. This has yielded the most significant enhancement to the knowledge of "in vivo" dose distributions in the patient. Furthermore, a much richer set of 3-D/4-D co-registered dose-image data is thus becoming available for retrospective analysis of radiobiological and clinical responses.

Initial Clinical Experience Performing Patient Treatment Verification With an Electronic Portal Imaging Device Transit Dosimeter

To prospectively evaluate a 2-dimensional transit dosimetry algorithm's performance on a patient population and to analyze the issues that would arise in a widespread clinical adoption of transit electronic portal imaging device (EPID) dosimetry. Eleven patients were enrolled on the protocol; 9 completed and were analyzed. Pretreatment intensity modulated radiation therapy (IMRT) patient-specific quality assurance was performed using a stringent local 3%, 3-mm γ criterion to verify that the planned fluence had been appropriately transferred to and delivered by the linear accelerator. Transit dosimetric EPID images were then acquired during treatment and compared offline with predicted transit images using a global 5%, 3-mm γ criterion. There were 288 transit images analyzed. The overall γ pass rate was 89.1%±9.8% (average±1 SD). For the subset of images for which the linear accelerator couch did not interfere with the measurement, the γ pass rate was 95.7%±2.4%. A case study is presented in which the transit dosimetry algorithm was able to identify that a lung patient's bilateral pleural effusion had resolved in the time between the planning CT scan and the treatment. The EPID transit dosimetry algorithm under consideration, previously described and verified in a phantom study, is feasible for use in treatment delivery verification for real patients. Two-dimensional EPID transit dosimetry can play an important role in indicating when a treatment delivery is inconsistent with the original plan.

Dosimetry in radiotherapy using a-Si EPIDs: Systems, methods, and applications focusing on 3D patient dose estimation

An overview is provided of the use of amorphous silicon electronic portal imaging devices (EPIDs) for dosimetric purposes in radiation therapy, focusing on 3D patient dose estimation. EPIDs were originally developed to provide on-treatment radiological imaging to assist with patient setup, but there has also been a natural interest in using them as dosimeters since they use the megavoltage therapy beam to form images. The current generation of clinically available EPID technology, amorphous-silicon (a-Si) flat panel imagers, possess many characteristics that make them much better suited to dosimetric applications than earlier EPID technologies. Features such as linearity with dose/dose rate, high spatial resolution, realtime capability, minimal optical glare, and digital operation combine with the convenience of a compact, retractable detector system directly mounted on the linear accelerator to provide a system that is well-suited to dosimetric applications. This review will discuss clinically available a-Si EPID systems, highlighting dosimetric characteristics and remaining limitations. Methods for using EPIDs in dosimetry applications will be discussed. Dosimetric applications using a-Si EPIDs to estimate three-dimensional dose in the patient during treatment will be overviewed. Clinics throughout the world are implementing increasingly complex treatments such as dynamic intensity modulated radiation therapy and volumetric modulated arc therapy, as well as specialized treatment techniques using large doses per fraction and short treatment courses (ie. hypofractionation and stereotactic radiosurgery). These factors drive the continued strong interest in using EPIDs as dosimeters for patient treatment verification.

Model‐based prediction of portal dose images during patient treatment

Dosimetric verification of radiation therapy is crucial when delivering complex treatments like intensity modulated radiation therapy (IMRT) or volumetric modulated arc therapy (VMAT. Pretreatment verification, characterized by methods applied without the patient present and before the treatment start date, is typically carried out at most centers. In vivo dosimetric verification, characterized by methods applied with the patient present, is not commonly carried out in the clinic. This work presents a novel, model-based EPID dosimetry method that could be used for routine clinical in vivo patient treatment verification. The authors integrated a detailed fluence model with a patient scatter prediction model that uses a superposition of scatter energy fluence kernels, generated via Monte Carlo techniques, to determine patient scatter fluence delivered to the EPID. The total dose to the EPID was calculated using the sum of convolutions of the calculated energy fluence distribution entering the EPID with monoenergetic dose kernels, specific to the a-Si EPID. Measured images with simple, square fields delivered to slab phantoms were validated against predicted images. Measured and predicted images acquired during the delivery of IMRT fields to slabs and an anthropomorphic phantom were compared using the χ-comparison for 3% dose difference and 3 mm distance-to-agreement criteria. Predicted and measured images of the square fields with slabs in the field agreed within 2.5%. Predicted portal dose images of clinical IMRT fields delivered to slabs and an anthropomorphic phantom agreed with measured images within 3% and 3 mm for an average of at least 97% of the infield pixels (defined as >10% maximum field dose) for each case, over all fields. This work presents the first validation of the integration of a comprehensive fluence model with a patient and EPID radiation transport model that accounts for patient transmission, including complex factors such as patient scatter and the energy response of the a-Si detector. The portal dose image prediction model satisfies the 3% and 3 mm criteria for IMRT fields delivered to slab phantoms and could be used for patient treatment verification.

TU‐E‐BRA‐02: How Should We Verify Complex Radiation Therapy Treatments ?

The critical importance of comprehensive treatment verification to patient safety is a topic of major current interest. The increase in complexity of modern treatments has created a direct need for correspondingly more sophisticated and comprehensive verification tools. A variety of new dosimetry techniques, QA devices, and verification rationale have recently emerged with potential to transform the process of both commissioning and routine patient treatment verification. A common goal of many of these systems is a more comprehensive measurement of the delivered dose in 3‐dimensions (3D) with high accuracy and spatial resolution. Several of these 3D or semi‐3D systems can also measure delivered dose in moving phantoms, and can therefore address important verification questions in 4D. Other approaches are capable of estimating the in‐vivo dose delivered to patients by back‐projecting measured exit fluence acquired during treatment. This symposium aims to review both the clinical rationale and clinical implementation of these important developments in complex treatment verification. Speakers will address the following topics in the context of clinical verification of advanced treatments like IMRT, VMAT/RapidArc, tomotherapy, and SRS/SBRT etc): 1) EPID dosimetry — both in‐vivo and ex‐vivo, 2) dosimetry with diode and chamber arrays, 3) 3D dosimetry with radiochromic plastics and gels, 4) computational algorithms for independent verification. The characteristics, state‐of‐the‐art, limitations, and clinical experience from these techniques will be reviewed.Learning objectives:1. gain insight into the dosimetric challenges posed by advanced radiation treatment techniques2. appreciate the importance of comprehensive treatment verification to patient safety3. understand the rationale and capabilities of dosimetry techniques for comprehensive treatment verification, both in‐vivo and ex‐vivo

Validation and automation of the DYNJAWS component module of the BEAMnrc Monte Carlo code

The purpose of this work is to validate and automate the use of DYNJAWS; a new component module (CM) in the BEAMnrc Monte Carlo (MC) user code. The DYNJAWS CM simulates dynamic wedges and can be used in three modes; dynamic, step-and-shoot and static. The step-and-shoot and dynamic modes require an additional input file defining the positions of the jaw that constitutes the dynamic wedge, at regular intervals during its motion. A method for automating the generation of the input file is presented which will allow for the more efficient use of the DYNJAWS CM. Wedged profiles have been measured and simulated for 6 and 10MV photons at three field sizes (5cm×5cm, 10cm×10cm and 20cm×20cm), four wedge angles (15°, 30°, 45° and 60°), at d (max) and at 10cm depth. Results of this study show agreement between the measured and the MC profiles to within 3% of absolute dose or 3mm distance to agreement for all wedge angles at both energies and depths. The gamma analysis suggests that dynamic mode is more accurate than the step-and-shoot mode. The DYNJAWS CM is an important addition to the BEAMnrc code and will enable the MC verification of patient treatments involving dynamic wedges.

SU‐GG‐T‐182: Two Years of Clinical Experience with DAVID ‐ A Translucent Multi‐Wire Detector for On‐Line Verification of Patient Treatments

Purpose: The DAVID system is used as an independent monitor system positioned between MLC and patient to assure the correct application of IMRT deliveries. In this work we report on our two year clinical experience with the system and will discuss detected treatment deviations and errors. Material and Methods: The DAVID system (PTW‐Freiburg, Germany) is a translucent multiwire transmission ionisation chamber, placed in the accessory holder of the linear accelerator. Each detection wire of the chamber is positioned in the projection line of a MLC leaf pair, resulting in a signal proportional to the line integral of the ionisation density (MLC opening). After the dosimetric verification of an IMRT plan, the values measured by all detection wires of the system are stored for each segment as reference values. During daily treatment the signals are re‐measured and compared to the reference values. A visual display of the readings and reference levels allows a fast overview about the correctness of the irradiation. Additionally a warning occurs if the predefined deviation level is exceeded. Results: The system is especially useful for all cases in which the MLC reproducibility is an issue such as in highly complex treatment deliveries. The permanent visual display of the signal in the control room has been established in our clinic as a reliable and fast tool, helping to identify errors that might not have been detected without this method. So far our experience with the system is based on the verification of approximately 50 IMRT plans with a total irradiated number of more than 60.000 sub‐segments over approximately 2 years. The main recorded deviations have been drifts of the linear accelerator output as well as block‐jaw and MLC decalibrations. In one case lost MLC segments resulting in a possible irradiation of open fields have been detected.

The angular dependence and effective point of measurement of a cylindrical scintillation dosimeter with and without a radio-opaque marker for brachytherapy

Fibre optic scintillation dosimeters, consisting of a plastic scintillator coupled to an optical fibre, are a promising dosimeter in brachytherapy applications. The combination of tissue equivalence, real-time readout and small spatial size makes them especially attractive for in vivo verification of patient treatments. Given that the orientation of the dosimeter with respect to the radioactive source changes during brachytherapy treatment, the angular dependence of the dosimeter is important. We derived the dependence of the response of a cylindrical dosimeter to a point radiation source as a function of distance along its axis and along a radius. Using the results, the effective point of measurement of a cylindrical scintillator was located for two points in the angular response curve as a function of distance between the source and dosimeter. We measured the angular response experimentally for a cylindrical scintillation dosimeter, when the source was located at a distance of 50 mm from the centre of the scintillator. A refinement of the design, in which a radio-opaque marker is incorporated into the tip for accurate localization in the patient, modifies the angular response of the dosimeter. For this new dosimeter design, we show that the dosimeter response decreases by 20% when the source is located on the axis of the scintillator, due to absorption by the marker. The dosimeter response becomes almost angle independent at 10° away from the axis. Excluding this cone, a cylindrical scintillation dosimeter which incorporates a radio-opaque marker was found to be angle independent to within 2%. In most clinical brachytherapy applications, this design has an acceptable angular dependence.

Dose comparison of megavoltage cone‐beam and orthogonal‐pair portal images

The technique of megavoltage cone‐beam computed tomography (MV CBCT) is available for image‐guided radiation therapy to improve the accuracy of patient setup and tumor localization. However, development of strategies to efficiently and effectively implement this technique or to replace the current orthogonal portal images technique remains challenging in the clinical environment. It is useful to compare the difference in absorbed dose between the MV CBCT technique and the orthogonal portal images technique, the current standard practice for treatment verification. Our study analyzed the doses generated from these two imaging techniques for six treatment sites (pelvis, abdomen, lung, head and neck, breast, prostate). The analysis was made by simulating the MV CBCT technique with an arc beam and a beam‐on time of 9 monitor units (MUs), and the orthogonal pair technique with a double‐exposure anterior–posterior and lateral pair and a beam‐on time of 4 MUs. The results are presented as dose per MU (cGy/MU) and absolute dose (cGy). The isocenter doses, integral doses, maximum doses, and mean doses to tumor and critical organs, and the two‐dimensional isodose distributions and dose–volume histograms of each critical organ were investigated. The absolute dose difference between MV CBCT and orthogonal pair at the isocenter was 4.02±0.59 cGy. Major differences were seen between the two techniques in critical organs whose locations are away from the tumor. These organs, such as the contralateral breast (difference: 0.17±0.10 cGy/MU) and lung (difference: 0.15±0.20 cGy/MU), receive a higher dose from MV CBCT images than from orthogonal portal images. Additionally, higher doses and larger dose areas involving more normal tissues were observed for MV CBCT images than for orthogonal portal images in our analysis methodology, which used 200 beam projections delivered from various angles for the MV CBCT simulation and from just two perpendicular angles for the orthogonal pair simulation. In our selected clinical cases, the high‐dose area from the orthogonal pair technique was always located inside the tumor; with MV CBCT, the high‐dose area will most likely be outside the tumor. Therefore, the potentially higher doses to critical organs from MV CBCT images should be properly analyzed to ensure that they do not exceed the tolerance dose when therapy is delivered using that technique. On the other hand, to obtain good image quality, the higher MUs with MV CBCT images may be necessary. The absorbed dose for the tumor and for other critical organs should be calculated accordingly in the treatment plans. Images by MV CBCT are a great tool for three‐dimensional verification of patient treatment position. The trade‐off is that the MV CBCT technique for patient treatment verification might have a higher chance of increasing the dose to normal tissue during image acquisition.PACS number: 87.53.Oq

Experimental verification of a portal dose prediction model

Electronic portal imaging devices (EPIDs) can be used to measure a two-dimensional (2D) dose distribution behind a patient, thus allowing dosimetric treatment verification. For this purpose we experimentally assessed the accuracy of a 2D portal dose prediction model based on pencil beam scatter kernels. A straightforward derivation of these pencil beam scatter kernels for portal dose prediction models is presented based on phantom measurements. The model is able to predict the 2D portal dose image (PDI) behind a patient, based on a PDI without the patient in the beam in combination with the radiological thickness of the patient, which requires in addition a PDI with the patient in the beam. To assess the accuracy of portal dose and radiological thickness values obtained with our model, various types of homogeneous as well as inhomogeneous phantoms were irradiated with a 6 MV photon beam. With our model we are able to predict a PDI with an accuracy better than 2% (mean difference) if the radiological thickness of the object in the beam is symmetrically situated around the isocenter. For other situations deviations up to 3% are observed for a homogeneous phantom with a radiological thickness of 17 cm and a 9 cm shift of the midplane-to-detector distance. The model can extract the radiological thickness within 7 mm (maximum difference) of the actual radiological thickness if the object is symmetrically distributed around the isocenter plane. This difference in radiological thickness is related to a primary portal dose difference of 3%. It can be concluded that our model can be used as an easy and accurate tool for the 2D verification of patient treatments by comparing predicted and measured PDIs. The model is also able to extract the primary portal dose with a high accuracy, which can be used as the input for a 3D dose reconstruction method based on back-projection.

Acceptance tests and quality control (QC) procedures for the clinical implementation of intensity modulated radiotherapy (IMRT) using inverse planning and the sliding window technique: experience from five radiotherapy departments

Background and purpose: An increasing number of radiotherapy centres is now aiming for clinical implementation of intensity modulated radiotherapy (IMRT), but – in contrast to conventional treatment – no national or international guidelines for commissioning of the treatment planning system (TPS) and acceptance tests of treatment equipment have yet been developed. This paper bundles the experience of five radiotherapy departments that have introduced IMRT into their clinical routine. Methods and materials: The five radiotherapy departments are using similar configurations since they adopted the commercially available Varian solution for IMRT, regarding treatment planning as well as treatment delivery. All are using the sliding window technique. Different approaches towards the derivation of the multileaf collimator (MLC) parameters required for the configuration of the TPS are described. A description of the quality control procedures for the dynamic MLC, including their respective frequencies, is given. For the acceptance of the TPS for IMRT multiple quality control plans were developed on a variety of phantoms, testing the flexibility of the inverse planning modules to produce the desired dose pattern as well as assessing the accuracy of the dose calculation. Regarding patient treatment verification, all five centres perform dosimetric pre-treatment verification of the treatment fields, be it on a single field or on a total plan procedure. During the actual treatment, the primary focus is on patient positioning rather than dosimetry. Intracavitary in vivo measurements were performed in special cases. Result and conclusion: The configurational MLC parameters obtained through different methods are not identical for all centres, but the observed variations have shown to be of no significant clinical relevance. The quality control (QC) procedures for the dMLC have not detected any discrepancies since their initiation, demonstrating the reliability of the MLC controller. The development of geometrically simple QC plans to test the inverse planning, the dynamic MLC modules and the final dose calculation has proven to be useful in pointing out the need to remodel the single pencil beam scatter kernels in some centres. The final correspondence between calculated and measured dose was found to be satisfactory by all centres, for QC test plans as well as for pre-treatment verification of clinical IMRT fields. An intercomparison of the man hours needed per patient plan verification reveals a substantial variation depending on the type of measurements performed.

A prototype 3D CT extension for radiotherapy simulators

In this paper we present a report on our custom 3D CT extension capable of producing fully 3D tomographic studies from conventional radiotherapy simulator cone-beam fluoro output. The extension consists of a common PC system on which a proprietary software toolkit provides the appropriate environment for reconstruction and acquisition of cone-beam data provided by commercial simulator fluoro video chains. The extension may compare favorably with CT options offered by simulator manufacturers: in particular, multi-slice single-scan reconstruction seems to be achievable while the current commercial solutions are based on single-slice single-scan. Radiotherapy applications include on-line treatment planning, patient treatment verification and registration.

Clinical use of on-line portal imaging for daily patient treatment verification

Purpose : To determine the ease of use by clinical staff and reliability of an electronic portal imaging system and evaluate the potential to utilize on-line imaging to assess accuracy of daily patient treatment positioning in radiation therapy. Methods and Materials : A computer controlled fluorescent screen-mirror imaging system was used to acquire online portal images. A physician panel assessed on-line image quality relative to standard portal film. Clinical use of the imager was implemented through a protocol where images were obtained during the first six monitor units of external beam. The images were visually compared to a reference portal and patient setup was adjusted for errors exceeding 5 mm. Subsequent off-line analysis was utilized to give insight into the magnitude of clinical setup error in the visually accepted images. Results : Physician evaluation of on-line image quality with an initial 211 images found that 70% were comparable or superior to standard film portal images. Eighty percent of treatment fields fit completely within the on-line imaging area. Eight percent of on-line images were rejected due to poor image quality. Twelve percent of the daily treatment setups imaged required adjustment overall, but specific field types predictably required more frequent adjustment (pelvic and mantle fields). Off-line analysis of accepted images demonstrates that 18% of the final images had setup errors exceeding 5 mm. Conclusion : On-line imaging facilitated daily portal alignment and verification. Ease of use, almost instantaneous viewing and consistent ability to identify and locate anatomical landmarks imply the potential for on-line imaging to replace film based approaches. Retrospective analysis of daily images reveals that visual assessment of setup is not sufficient for eliminating localization errors. Further improvement is required with respect to detecting localization error and fully encompassing larger field sizes.